Regeneron And Bluebird Team To Invent New Cell Therapies For Cancer

Regeneron Pharmaceuticals, the $5.9 billion (sales) Tarrytown, N.Y.-based biotech firm , and gene therapy upstart Bluebird Bio will team up to invent genetically modified white blood cells that can attack cancer -- a technology known as CAR-T cells.